1. Scrip
  2. >>Leadership

Getting Women On Boards: LifeSci Advisors' After-Party Mission Is Valued - But Achieving Results Is Hard

 
• By Eleanor Malone

LifeSci Advisors has thrown its back into getting more women on boards, and its efforts have been praised. However, with just 13 women placed in a year and a half, the task is not an easy one.  

SC1803_Annual Report_94009225_1200.jpg
can the boardroom's historic gender bias be overcome? • Source: Shutterstock

The public condemnation of LifeSci Advisors' employment of female models at its now-notorious cocktail party during the J.P. Morgan conference of 2016 led to the Damascene conversion of founding partner Mike Rice. Turning his back on sexist social events, Rice formed an alliance with venture capitalist Kate Bingham after she co-authored a public rebuke to the biotech communications advisory firm. He is now committed to promoting women's representation in biotech boardrooms.

Scrip caught up with Rice and Bingham to find out what LifeSci Advisors has achieved since it gave up recruiting...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

Bristol Appoints AstraZeneca’s Massacesi As Next CMO

 
• By Jessica Merrill

Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

Executives On The Move: Three New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Trogenix and Quetzal Therapeutics, plus Synendos Therapeutics gains a new CMO from Roche.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Abivax Over The Moon As Obefazimod Storms Phase III

 
• By Kevin Grogan

Stock shoots up over 460% on positive results in two ulcerative colitis trials of the oral first-in-class candidate.

More from Scrip

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By Kevin Grogan

Comes Days After PDUFA Pushback For GSK's Blenrep.

Pipeline Watch: Twelve Approvals And Six Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Private Equity Targets Bavarian Nordic But Major Investor Balks

 
• By Manas Mishra

After “intense negotiations”, Bavarian Nordic’s board plans to recommend a DKK19bn ($2.98bn) offer by private equity firms Nordic Capital and Permira to take the company private.